<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335048</url>
  </required_header>
  <id_info>
    <org_study_id>6332011</org_study_id>
    <nct_id>NCT01335048</nct_id>
  </id_info>
  <brief_title>Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity</brief_title>
  <acronym>ACHIDO</acronym>
  <official_title>Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Misericordia e Dolce</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Misericordia e Dolce</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an
      adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable
      patients with high on-treatment reactivity according to a point-of-care platelet function
      assay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, open-label, control-active trial performed in elective
      patients candidates to coronary drug eluting stent implantation who presented
      high-on-treatment platelet reactivity, immediately before coronary intervention (PCI). All
      patients are treated with aspirin (100 mg/day) and standard-dose clopidogrel (600 mg as
      loading dose and 75 mg daily as maintenance dose)for at least 7 days before PCI. Platelet
      function is assessed by the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA). Patients are
      eligible to be enrolled if they have high-on-treatment reactivity defined as P2Y12 reaction
      units (PRU) &gt;= 230, immediately before PCI. After PCI, patients are randomized to receive
      high-dose clopidogrel (150 mg daily) or high-dose atorvastatin (80mg/day) + high-dose
      clopidogrel (150 mg daily). Study visits and platelet function testing with the VerifyNow
      P2Y12 test are conducted at 7 and 30 days after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in on-treatment platelet reactivity at 7 and 30 days</measure>
    <time_frame>pre-PCI, 7 days and 30 days</time_frame>
    <description>Pharmacodynamic analysis of the randomized groups includes a) assessment of the absolute level of on-treatment reactivity, b) change in on-treatment reactivity, c) rate of high on-treatment reactivity at 7 and 30 days. The platelet reactivity is measured with the VerifyNow P2Y12 test (Accumetrics, SanDiego, CA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>Atorvastatin-Clopidogrel group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who receive clopidogrel 150 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin and clopidogrel</intervention_name>
    <description>Atorvastatin 80 mg daily + clopidogrel 150 mg daily</description>
    <arm_group_label>Atorvastatin-Clopidogrel group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 150 mg daily</description>
    <arm_group_label>Clopidogrel group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable angina

          -  candidates to drug eluting stent implantation

          -  High on-treatment platelet reactivity according to a point-of-care platelet function
             test

        Exclusion Criteria:

          -  chronic therapy with statins

          -  inability to provide informed consent

          -  intolerance to statins

          -  acute or chronic liver failure or ALT &gt; 2 times ULN

          -  known myopathy

          -  CKD stage IV or dialysis treatment

          -  pregnancy or breast-feeding

          -  malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Leoncini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Misericordia e Dolce, Prato</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Toso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Misericordia e Dolce, Prato</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Department, Ospedale Misericordia e Dolce</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Misericordia e Dolce</investigator_affiliation>
    <investigator_full_name>Toso Anna</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Statins</keyword>
  <keyword>Platelet reactivity</keyword>
  <keyword>Point-of-care platelet function test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

